Feel Comfortable Not Giving Alirocumab During Hospitalization

Alirocumab (Praluent, PRAL-you-ent) is the first "PCSK9 inhibitor" for high cholesterol.

It works by preventing PCSK9...proprotein convertase subtilisin kexin type 9...from binding and degrading liver LDL receptors. This leads to more LDL receptors...and more LDL cholesterol clearing from the blood.

Alirocumab can lower LDL by about 60%, regardless of statin use.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals